Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
Parkinson's disease
rating scale
validation
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
04
09
2021
accepted:
06
11
2021
pubmed:
27
2
2022
medline:
20
4
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has become the gold standard for evaluating different domains in Parkinson's disease (PD), and it is commonly used in clinical practice, research, and clinical trials. The objectives are to validate the Arabic-translated version of the MDS-UPDRS and to assess its factor structure compared with the English version. The study was carried out in three phases: first, the English version of the MDS-UPDRS was translated into Arabic and subsequently back-translated into English by independent translation team; second, cognitive pretesting of selected items was performed; third, the Arabic version was tested in over 400 native Arabic-speaking PD patients. The psychometric properties of the translated version were analyzed using confirmatory factor analysis (CFA) as well as exploratory factor analysis (EFA). The factor structure of the Arabic version was consistent with that of the English version based on the high CFIs for all four parts of the MDS-UPDRS in the CFA (CFI ≥0.90), confirming its suitability for use in Arabic. The Arabic version of the MDS-UPDRS has good construct validity in Arabic-speaking patients with PD and has been thereby designated as an official MDS-UPDRS version. The data collection methodology among Arabic-speaking countries across two continents of Asia and Africa provides a roadmap for validating additional MDS rating scale initiatives and is strong evidence that underserved regions can be energically mobilized to promote efforts that apply to better clinical care, education, and research for PD. © 2022 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has become the gold standard for evaluating different domains in Parkinson's disease (PD), and it is commonly used in clinical practice, research, and clinical trials.
OBJECTIVES
The objectives are to validate the Arabic-translated version of the MDS-UPDRS and to assess its factor structure compared with the English version.
METHODS
The study was carried out in three phases: first, the English version of the MDS-UPDRS was translated into Arabic and subsequently back-translated into English by independent translation team; second, cognitive pretesting of selected items was performed; third, the Arabic version was tested in over 400 native Arabic-speaking PD patients. The psychometric properties of the translated version were analyzed using confirmatory factor analysis (CFA) as well as exploratory factor analysis (EFA).
RESULTS
The factor structure of the Arabic version was consistent with that of the English version based on the high CFIs for all four parts of the MDS-UPDRS in the CFA (CFI ≥0.90), confirming its suitability for use in Arabic.
CONCLUSIONS
The Arabic version of the MDS-UPDRS has good construct validity in Arabic-speaking patients with PD and has been thereby designated as an official MDS-UPDRS version. The data collection methodology among Arabic-speaking countries across two continents of Asia and Africa provides a roadmap for validating additional MDS rating scale initiatives and is strong evidence that underserved regions can be energically mobilized to promote efforts that apply to better clinical care, education, and research for PD. © 2022 International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-841Informations de copyright
© 2022 International Parkinson and Movement Disorder Society.
Références
Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's disease rating scale (MDS-UPDRS). J Neurol 2013;260(1):228-236.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
Martínez-Martín P, Rodríguez-Blázquez C, Forjaz M, Alvarez-Sánchez M, Arakaki T, Bergareche-Yarza A, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol 2014;21(3):519-524.
Goetz CG, Liu Y, Stebbins GT, Wang L, Tilley BC, Teresi JA, et al. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale. Mov Disord 2016;31(12):1865-1873.
Goetz CG, Luo S, Wang L, Tilley BC, LaPelle NR, Stebbins GT. Handling missing values in the MDS-UPDRS. Mov Disord 2015;30(12):1632-1638.
Horváth K, Aschermann Z, Kovács M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale. Mov Disord 2017;32(5):789-793.
Horváth K, Aschermann Z, Ács P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord 2015;21(12):1421-1426.
Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Movement disorders clinical practice 2017;4(4):536-544.
Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the movement disorder society-sponsored revision of the unified Parkinson's disease rating scale:(MDS-UPDRS). Mov Disord 2010;25(9):1190-1194.
Goetz CG, Stebbins GT, Wang L, LaPelle NR, Luo S, Tilley BC. IPMDS-sponsored scale translation program: process, format, and clinimetric testing plan for the MDS-UPDRS and UDysRS. Mov Disord Clinic Pract. 2014;1(2):97-101.
Bureau. USC 2015;Pages http://www.census.gov/data/tables/2013/demo/2009-2013-lang-tables.html Accessed on August 13, 2016.
Organization WH;Pages. http://www.who.int/about/multilingualism/en/ Accessed on August 13, 2016. 2016.
Tilley BC, LaPelle NR, Goetz CG, Stebbins GT. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society unified Parkinson's disease rating scale (MDS-UPDRS) example. J Parkinsons Dis 2014;4(3):395-404.
Muthén LK, Muthén BO. Mplus Version 7 user's guide. Los Angeles, CA: Muthén & Muthén; 2012.
Brown TA. Confirmatory factor analysis for applied research. Guilford publications. 2015.
Browne MW. An overview of analytic rotation in exploratory factor analysis. Multivar Behav Res 2001;36(1):111-150.
O'Rourke N, Hatcher L. A step-by-step approach to using SAS for factor analysis and structural equation modeling. Sas Institute. 2013.
Kirmayer LJ, Ryder AG. Culture and psychopathology. Curr Opin Psychol 2016;8:143-148.
Scult MA, Paulli AR, Mazure ES, Moffitt TE, Hariri AR, Strauman TJ. The association between cognitive function and subsequent depression: a systematic review and meta-analysis. Psychol Med 2017;47(1):1
Petkus AJ, Filoteo JV, Schiehser DM, Gomez ME, Hui JS, Jarrahi B, et al. Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson's disease. Int J Geriatr Psychiatry 2020;35(4):396-404.
Shetty AS, Bhatia KP, Lang AE. Dystonia and Parkinson's disease: what is the relationship? Neurobiol Dis 2019;132:104462
Noack R, Gamio L. The world's languages, in 7 maps and charts. Wash Post 2015;4(23):65-70.